Spotlight on Neurology

Credits: 1.00 CME
Patient-Centered, Multidisciplinary Approaches to Optimize Outcomes in Patients with Multiple Sclerosis
Patricia K. Coyle, MD
Integrity Continuing Education, Inc.

Patient-Centered, Multidisciplinary Approaches to Optimize Outcomes in Patients with Multiple Sclerosis

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 1, 2020
Expires: April 1, 2021
60 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for neurologists, Multiple Sclerosis (MS) specialists, certified neurology nurse practitioners, and other healthcare professionals who treat patients with MS.

Learning Objectives

  • ELUCIDATE the rationale behind early, individualized treatment of active MS disease
  • CONSTRUCT a risk/benefit analysis across current, newly approved and emerging MS therapies based on an understanding of MOAs, effects, safety, and efficacy in order to better individualize a patient’s treatment plan
  • APPLY evidence-based strategies for educating and counseling MS patients about pharmacological options and lifestyle approaches to improving health-related quality of life
  • IMPLEMENT a multidisciplinary treatment strategy involving methods for effective shared decision-making about MS DMTs

Activity Description

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this multimedia case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. The availability of DMT has revolutionized the care of patients with MS; however, more than a dozen DMTs are currently FDA-approved, with several more undergoing late-stage clinical trials. With no head-to-head trials of DMTs, clinicians are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. Clinical practice guidelines were released in early 2018 by the AAN, and many clinicians require education on the new recommendations. To address the multisystem nature of MS, clinicians must be prepared to coordinate care within a multidisciplinary team, and shared decision-making with a patient-centric approach is a critical component of effective care.

Faculty

Patricia K. Coyle, MD
Professor of Neurology and Vice Chair of Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Patricia K. Coyle, MD
Consulting Fees: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, TG Therapeutics
Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 1, 2020 through April 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 1, 2020
Expires: April 1, 2021
60 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for neurologists, Multiple Sclerosis (MS) specialists, certified neurology nurse practitioners, and other healthcare professionals who treat patients with MS.

Learning Objectives

  • ELUCIDATE the rationale behind early, individualized treatment of active MS disease
  • CONSTRUCT a risk/benefit analysis across current, newly approved and emerging MS therapies based on an understanding of MOAs, effects, safety, and efficacy in order to better individualize a patient’s treatment plan
  • APPLY evidence-based strategies for educating and counseling MS patients about pharmacological options and lifestyle approaches to improving health-related quality of life
  • IMPLEMENT a multidisciplinary treatment strategy involving methods for effective shared decision-making about MS DMTs

Activity Description

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this multimedia case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. The availability of DMT has revolutionized the care of patients with MS; however, more than a dozen DMTs are currently FDA-approved, with several more undergoing late-stage clinical trials. With no head-to-head trials of DMTs, clinicians are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. Clinical practice guidelines were released in early 2018 by the AAN, and many clinicians require education on the new recommendations. To address the multisystem nature of MS, clinicians must be prepared to coordinate care within a multidisciplinary team, and shared decision-making with a patient-centric approach is a critical component of effective care.

Faculty

Patricia K. Coyle, MD
Professor of Neurology and Vice Chair of Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Patricia K. Coyle, MD
Consulting Fees: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, TG Therapeutics
Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 1, 2020 through April 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Neurology Presentations

0.25 CME
The France Foundation
Gene Therapy for SMA: Data, Implications, and Global Perspectives — Importance of Early Diagnosis and Screening in SMA

Gene Therapy for SMA: Data, Implications, and Global Perspectives — Importance of Early Diagnosis and Screening in SMA

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explore potential implications of gene therapy for SMA

Activity Description

This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explore potential implications of gene therapy for SMA

Activity Description

This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME
The France Foundation
Gene Therapy for SMA: Data, Implications, and Global Perspectives — Gene Therapy in SMA: How it Works and Potential Implications

Gene Therapy for SMA: Data, Implications, and Global Perspectives — Gene Therapy in SMA: How it Works and Potential Implications

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explain how gene therapy works

Activity Description

This education describes various approaches to gene therapy in SMA and reviews clinical trials and data, which continues to accumulate.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explain how gene therapy works

Activity Description

This education describes various approaches to gene therapy in SMA and reviews clinical trials and data, which continues to accumulate.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME
The France Foundation
Gene Therapy for SMA: Data, Implications, and Global Perspectives — SMA: Introduction and Key Concepts

Gene Therapy for SMA: Data, Implications, and Global Perspectives — SMA: Introduction and Key Concepts

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Describe criteria for SMA diagnosis
  • Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Describe criteria for SMA diagnosis
  • Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME
The France Foundation
Controversies in Progressive MS – Managing Progressive Disease

Controversies in Progressive MS – Managing Progressive Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Fred D. Lublin, MD, FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Fred D. Lublin, MD, FAAN, FANA, has served as a speaker for Sanofi. He has done research for Actelion, Biogen, Brainstorm Cell Therapeutics, The National Institute of Health, The National Multiple Sclerosis Society, Novartis Pharmaceuticals, and Sanofi. He has also consulted and served on advisory boards for Acorda, Actelion/Janssen, Apitope, Atara, Avotres, Biotherapeutics, Biogen, Brainstorm Cell Therapeutics, EMD Serono, GW Pharma, Immunic, Innate Immunotherapeutics, Jazz Pharmaceuticals, Mapi Pharma, MedDay, MedImmune/Viela Bio, Mylan, Novartis, Orion Biotechnology, Polpharma, Population Council, Receptos/Celgene, Roche/Genentech, Sanofi/Genzyme, Teva, and TG Therapeutics.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Fred D. Lublin, MD, FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Fred D. Lublin, MD, FAAN, FANA, has served as a speaker for Sanofi. He has done research for Actelion, Biogen, Brainstorm Cell Therapeutics, The National Institute of Health, The National Multiple Sclerosis Society, Novartis Pharmaceuticals, and Sanofi. He has also consulted and served on advisory boards for Acorda, Actelion/Janssen, Apitope, Atara, Avotres, Biotherapeutics, Biogen, Brainstorm Cell Therapeutics, EMD Serono, GW Pharma, Immunic, Innate Immunotherapeutics, Jazz Pharmaceuticals, Mapi Pharma, MedDay, MedImmune/Viela Bio, Mylan, Novartis, Orion Biotechnology, Polpharma, Population Council, Receptos/Celgene, Roche/Genentech, Sanofi/Genzyme, Teva, and TG Therapeutics.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME
The France Foundation
Controversies in Progressive MS – Transition to Progressive Disease

Controversies in Progressive MS – Transition to Progressive Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia Melville, RN, MSN, NP-C, MSCN
Clinical Instructor
Department of Neurology
SUNY at Stony Brook
Stony Brook, New York


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Patricia Melville, RN, MSN, NP-C, MSCN, has served as a consultant for Biogen, EMD Serono, Sanofi-Genzyme, Roche/Genentech, Novartis, and Celgene. She has also done contract research for Corrona LLC, Biogen, MedDay Pharmaceuticals, Novartis, Roche/Genentech, and Johnson & Johnson.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia Melville, RN, MSN, NP-C, MSCN
Clinical Instructor
Department of Neurology
SUNY at Stony Brook
Stony Brook, New York


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Patricia Melville, RN, MSN, NP-C, MSCN, has served as a consultant for Biogen, EMD Serono, Sanofi-Genzyme, Roche/Genentech, Novartis, and Celgene. She has also done contract research for Corrona LLC, Biogen, MedDay Pharmaceuticals, Novartis, Roche/Genentech, and Johnson & Johnson.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME
The France Foundation
Controversies in Progressive MS – Focus on Diagnosis

Controversies in Progressive MS – Focus on Diagnosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia K. Coyle, MD
Director, MS Comprehensive Care Center
Professor of Neurology
Stony Brook University
Stony Brook, New York


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Patricia K. Coyle, MD, has served as a consultant for Accordant, Alexion, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics. She has also done research for Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, and Novartis.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 26, 2020
Expires: June 25, 2021
15 minutes to complete

Learning Objectives

Upon completion of the activity participants should be able to:

  • Diagnose MS accurately and understand the importance of timely initiation of treatment
  • Recognize early signs of disease progression and understand the importance of long-term surveillance
  • Review current and emerging DMTs for the management of MS
  • Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia K. Coyle, MD
Director, MS Comprehensive Care Center
Professor of Neurology
Stony Brook University
Stony Brook, New York


Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

 

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

  • Patricia K. Coyle, MD, has served as a consultant for Accordant, Alexion, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics. She has also done research for Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, and Novartis.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

1.00 CME
Forefront Collaborative
Exploring Within: A Mixed Reality Look Into Migraine and Episodic Cluster

Exploring Within: A Mixed Reality Look Into Migraine and Episodic Cluster

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 13, 2020
Expires: April 13, 2021
60 minutes to complete

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

  • Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
  • Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
  • Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
  • Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

  • Welcome and Session Overview
  • Pathophysiology and Mechanism of Action Depicted in Mixed Reality
  • Cases in Episodic Migraine and Episodic Cluster Headache
  • Question and Answer Session
  • Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois


Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planner (Forefront Collaborative): Sydney Pate, MS
  • Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
  • Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
  • Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
  • Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
  • Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 13, 2020
Expires: April 13, 2021
60 minutes to complete

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

  • Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
  • Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
  • Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
  • Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

  • Welcome and Session Overview
  • Pathophysiology and Mechanism of Action Depicted in Mixed Reality
  • Cases in Episodic Migraine and Episodic Cluster Headache
  • Question and Answer Session
  • Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois


Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planner (Forefront Collaborative): Sydney Pate, MS
  • Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
  • Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
  • Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
  • Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
  • Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

1.00 CME
Integrity Continuing Education, Inc.
Patient-Centered, Multidisciplinary Approaches to Optimize Outcomes in Patients with Multiple Sclerosis

Patient-Centered, Multidisciplinary Approaches to Optimize Outcomes in Patients with Multiple Sclerosis

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 1, 2020
Expires: April 1, 2021
60 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for neurologists, Multiple Sclerosis (MS) specialists, certified neurology nurse practitioners, and other healthcare professionals who treat patients with MS.

Learning Objectives

  • ELUCIDATE the rationale behind early, individualized treatment of active MS disease
  • CONSTRUCT a risk/benefit analysis across current, newly approved and emerging MS therapies based on an understanding of MOAs, effects, safety, and efficacy in order to better individualize a patient’s treatment plan
  • APPLY evidence-based strategies for educating and counseling MS patients about pharmacological options and lifestyle approaches to improving health-related quality of life
  • IMPLEMENT a multidisciplinary treatment strategy involving methods for effective shared decision-making about MS DMTs

Activity Description

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this multimedia case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. The availability of DMT has revolutionized the care of patients with MS; however, more than a dozen DMTs are currently FDA-approved, with several more undergoing late-stage clinical trials. With no head-to-head trials of DMTs, clinicians are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. Clinical practice guidelines were released in early 2018 by the AAN, and many clinicians require education on the new recommendations. To address the multisystem nature of MS, clinicians must be prepared to coordinate care within a multidisciplinary team, and shared decision-making with a patient-centric approach is a critical component of effective care.

Faculty

Patricia K. Coyle, MD
Professor of Neurology and Vice Chair of Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Patricia K. Coyle, MD
Consulting Fees: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, TG Therapeutics
Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 1, 2020 through April 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 1, 2020
Expires: April 1, 2021
60 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for neurologists, Multiple Sclerosis (MS) specialists, certified neurology nurse practitioners, and other healthcare professionals who treat patients with MS.

Learning Objectives

  • ELUCIDATE the rationale behind early, individualized treatment of active MS disease
  • CONSTRUCT a risk/benefit analysis across current, newly approved and emerging MS therapies based on an understanding of MOAs, effects, safety, and efficacy in order to better individualize a patient’s treatment plan
  • APPLY evidence-based strategies for educating and counseling MS patients about pharmacological options and lifestyle approaches to improving health-related quality of life
  • IMPLEMENT a multidisciplinary treatment strategy involving methods for effective shared decision-making about MS DMTs

Activity Description

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this multimedia case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. The availability of DMT has revolutionized the care of patients with MS; however, more than a dozen DMTs are currently FDA-approved, with several more undergoing late-stage clinical trials. With no head-to-head trials of DMTs, clinicians are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. Clinical practice guidelines were released in early 2018 by the AAN, and many clinicians require education on the new recommendations. To address the multisystem nature of MS, clinicians must be prepared to coordinate care within a multidisciplinary team, and shared decision-making with a patient-centric approach is a critical component of effective care.

Faculty

Patricia K. Coyle, MD
Professor of Neurology and Vice Chair of Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Patricia K. Coyle, MD
Consulting Fees: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, TG Therapeutics
Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 1, 2020 through April 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

1.00 CME
Vindico
Limb Girdle Muscular Dystrophies – A Deep Dive Into Molecular Causes, Symptoms, and Testing by Subtype

Limb Girdle Muscular Dystrophies – A Deep Dive Into Molecular Causes, Symptoms, and Testing by Subtype

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: March 31, 2020
Expires: March 30, 2021
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuromuscular specialists, pediatricians, and other health care professionals involved in the management of patients with limb-girdle muscular dystrophies (LGMD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Evaluate the genetic and molecular causes of the major subtypes of LGMD as well as the clinical implications for patients.
  • Examine the heterogeneity in symptoms experienced by patients with LGMD and the implications for patient management.
  • Assess appropriate tests and medical work-up to aid in the timely and accurate subtype diagnosis for patients with LGMD.

Activity Description

Limb girdle muscular dystrophies (LGMD) are a group of rare neuromuscular disorders characterized by weakness and wasting of the muscles in the shoulder and pelvic girdles. The severity, age of onset, and heterogeneity are determined by mutations in various genes. To date, there are no disease-modifying options for patients with LGMD; instead, management is based on multidisciplinary care to treat the symptoms and prevent further progression. As the science surrounding LGMD and its treatment continues to evolve, it is imperative that neurologists and other providers understand the mechanisms of disease, the difference in subtypes, and how to achieve accurate diagnosis. To address these topics, experts on LGMD will present a web-based educational activity featuring multidisciplinary perspectives.

Agenda

  • Introduction
  • Limb Girdle Molecular Dystrophies - Prevalence and Symptoms
  • Genetic Causes of LGMD - Implications for Disease Heterogeneity and Diagnosis
  • Achieving Accurate Subtype Diagnosis in LGMD - A Discussion of Best Practices
  • Conclusion

Activity Chair

Matthew P. Wicklund, MD
Professor of Neurology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Consulting Fee: Sarepta
Contracted Research: Muscular Dystrophy Association
Ownership Interest: Myonexuss

Faculty

Nicholas Johnson, MD, MSCI
Vice Chair of Research
Associate Professor
Virginia Commonwealth University
Richmond, VA

Disclosure:
Intellectual Property/Patent Details: University of Rochester
Consulting Fee: AskBio, AveXis, Dyne, ML Bio Solutions, Sarepta, Triplett, Vertex
Contracted Research: AveXis, ML Bio Solutions, Sarepta, Vertex
Ownership Interest: ML Bio Solutions


Monkol Lek, PhD
Assistant Professor
Yale University School of Medicine
New Haven, CT

Disclosure:
No relevant financial relationships to disclose.


Katherine D. Mathews, MD
Professor, Departments of Pediatrics and Neurology
Vice Chair for Clinical Research, Department of Pediatrics
University of Iowa Carver College of Medicine
Iowa City, IA

Disclosure:
Consulting Fee (paid to institution): Asklepios, AveXis, Santhera, Sarepta
Contracted Research: Hoffmann-La Roche, Pfizer, PTC Therapeutics, Santhera, Sarepta, Wave

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

  • Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sarepta Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: March 31, 2020
Expires: March 30, 2021
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuromuscular specialists, pediatricians, and other health care professionals involved in the management of patients with limb-girdle muscular dystrophies (LGMD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Evaluate the genetic and molecular causes of the major subtypes of LGMD as well as the clinical implications for patients.
  • Examine the heterogeneity in symptoms experienced by patients with LGMD and the implications for patient management.
  • Assess appropriate tests and medical work-up to aid in the timely and accurate subtype diagnosis for patients with LGMD.

Activity Description

Limb girdle muscular dystrophies (LGMD) are a group of rare neuromuscular disorders characterized by weakness and wasting of the muscles in the shoulder and pelvic girdles. The severity, age of onset, and heterogeneity are determined by mutations in various genes. To date, there are no disease-modifying options for patients with LGMD; instead, management is based on multidisciplinary care to treat the symptoms and prevent further progression. As the science surrounding LGMD and its treatment continues to evolve, it is imperative that neurologists and other providers understand the mechanisms of disease, the difference in subtypes, and how to achieve accurate diagnosis. To address these topics, experts on LGMD will present a web-based educational activity featuring multidisciplinary perspectives.

Agenda

  • Introduction
  • Limb Girdle Molecular Dystrophies - Prevalence and Symptoms
  • Genetic Causes of LGMD - Implications for Disease Heterogeneity and Diagnosis
  • Achieving Accurate Subtype Diagnosis in LGMD - A Discussion of Best Practices
  • Conclusion

Activity Chair

Matthew P. Wicklund, MD
Professor of Neurology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Consulting Fee: Sarepta
Contracted Research: Muscular Dystrophy Association
Ownership Interest: Myonexuss

Faculty

Nicholas Johnson, MD, MSCI
Vice Chair of Research
Associate Professor
Virginia Commonwealth University
Richmond, VA

Disclosure:
Intellectual Property/Patent Details: University of Rochester
Consulting Fee: AskBio, AveXis, Dyne, ML Bio Solutions, Sarepta, Triplett, Vertex
Contracted Research: AveXis, ML Bio Solutions, Sarepta, Vertex
Ownership Interest: ML Bio Solutions


Monkol Lek, PhD
Assistant Professor
Yale University School of Medicine
New Haven, CT

Disclosure:
No relevant financial relationships to disclose.


Katherine D. Mathews, MD
Professor, Departments of Pediatrics and Neurology
Vice Chair for Clinical Research, Department of Pediatrics
University of Iowa Carver College of Medicine
Iowa City, IA

Disclosure:
Consulting Fee (paid to institution): Asklepios, AveXis, Santhera, Sarepta
Contracted Research: Hoffmann-La Roche, Pfizer, PTC Therapeutics, Santhera, Sarepta, Wave

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

  • Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sarepta Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Sarcoidosis: Considerations in the Management of Refractory Disease - Neurosarcoidosis

Sarcoidosis: Considerations in the Management of Refractory Disease - Neurosarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Neurosarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Neurosarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages